Lymphotoxin-Β Interacts With Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-1955
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Nuclear EGFR Contributes to Acquired Resistance to Cetuximab

Oncogene
Cancer ResearchGeneticsMolecular Biology
2009English

Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel in Vivo Model of Acquired Cetuximab Resistance

Clinical Cancer Research
Cancer ResearchOncology
2011English

ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2014English

Phase 1 Study of EGFR-antisense DNA, Cetuximab, and Radiotherapy in Head and Neck Cancer With Preclinical Correlatives

Cancer
Cancer ResearchOncology
2018English

Cetuximab Promotes Epithelial to Mesenchymal Transition and Cancer Associated Fibroblasts in Patients With Head and Neck Cancer

Oncotarget
Oncology
2015English

Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer

New England Journal of Medicine
Medicine
2008English

Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer

Clinical Cancer Research
Cancer ResearchOncology
2017English

Cetuximab in Locally Advanced Head-And-Neck Cancer: Defining the Population

Current Oncology
Oncology
2010English

Mechanisms of Acquired Resistance to EGFR-tyrosine Kinase Inhibitor in Korean Patients With Lung Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy